GSTC (GlobeStar Therapeutics) Short-Term Debt: $0.33 Mil (As of Jun. 2024)


What is GlobeStar Therapeutics Short-Term Debt?

GlobeStar Therapeutics GSTC -99.00% Short-Term Debt is $0.33 Mil as of Jun. 2024.

GlobeStar Therapeutics's Short-Term Debt for the quarter that ended in Jun. 2024 was $0.33 Mil.

GlobeStar Therapeutics's quarterly Short-Term Debt declined from Dec. 2023 ($0.38 Mil) to Mar. 2024 ($0.34 Mil) and declined from Mar. 2024 ($0.34 Mil) to Jun. 2024 ($0.33 Mil).

GlobeStar Therapeutics's annual Short-Term Debt increased from Sep. 2021 ($0.02 Mil) to Sep. 2022 ($0.03 Mil) and increased from Sep. 2022 ($0.03 Mil) to Sep. 2023 ($0.37 Mil).

GlobeStar Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

GlobeStar Therapeutics Short-Term Debt Related Terms

GlobeStar Therapeutics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for GlobeStar Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlobeStar Therapeutics Short-Term Debt Chart

GlobeStar Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.16 0.02 0.03 0.37

GlobeStar Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.37 0.38 0.34 0.33
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.33 Mil mean?
GlobeStar Therapeutics (GSTC) has a Short-Term Debt of $0.33 Mil as of Jun. 2024.
Is GlobeStar Therapeutics' Short-Term Debt too high?
GlobeStar Therapeutics' current Short-Term Debt is $0.33 Mil.
How does GlobeStar Therapeutics' Short-Term Debt compare to GBLX and ENDV?
GlobeStar Therapeutics' Short-Term Debt of $0.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. GlobeStar Therapeutics's current Short-Term Debt is $0.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlobeStar Therapeutics stock overvalued right now?
GlobeStar Therapeutics (GSTC) has a current Short-Term Debt of $0.33 Mil. The current Short-Term Debt is $0.33 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For GlobeStar Therapeutics (GSTC), the current Short-Term Debt is $0.33 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GlobeStar Therapeutics Business Description

Address 719 Jadewin Avenue, Richland, WA, USA, 99352
GlobeStar Therapeutics Corp is a clinical-stage pharmaceutical company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The company is focused on developing therapies for people with serious and life-threatening rare disorders.